162 related articles for article (PubMed ID: 21748722)
1. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.
Aramwit P; Srisawadwong R; Supasyndh O
J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722
[TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
3. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
[TBL] [Abstract][Full Text] [Related]
4. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
Bostom AG; Maclean AA; Maccubbin D; Tipping D; Giezek H; Hanlon WA
J Clin Lipidol; 2011; 5(4):281-7. PubMed ID: 21784373
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
[TBL] [Abstract][Full Text] [Related]
6. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
Koiwa F; Terao A
Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
[TBL] [Abstract][Full Text] [Related]
8. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
9. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
[TBL] [Abstract][Full Text] [Related]
10. Dietary intervention focused on phosphate intake in hemodialysis patients with hyperphosphoremia.
Lou LM; Caverni A; Gimeno JA; Moreno R; Pérez J; Alvarez R; Campos B; García M; Gutiérrez A; Bielsa S; Castilla J; Sanz A; Martin F;
Clin Nephrol; 2012 Jun; 77(6):476-83. PubMed ID: 22595390
[TBL] [Abstract][Full Text] [Related]
11. [Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia].
Restrepo Valencia CA; Cruz J
Nefrologia; 2008; 28(1):61-6. PubMed ID: 18336133
[TBL] [Abstract][Full Text] [Related]
12. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
Maccubbin D; Tipping D; Kuznetsova O; Hanlon WA; Bostom AG
Clin J Am Soc Nephrol; 2010 Apr; 5(4):582-9. PubMed ID: 20299362
[TBL] [Abstract][Full Text] [Related]
13. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
14. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
[TBL] [Abstract][Full Text] [Related]
15. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
[TBL] [Abstract][Full Text] [Related]
16. Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.
Rennick A; Kalakeche R; Seel L; Shepler B
Pharmacotherapy; 2013 Jun; 33(6):683-90. PubMed ID: 23526664
[TBL] [Abstract][Full Text] [Related]
17. The effect of intravenous vitamin C on the phosphorus level reduction in hemodialysis patients: a double blind randomized clinical trial.
Gholipour Baradari A; Emami Zeydi A; Espahbodi F; Aarabi M
Med Glas (Zenica); 2012 Feb; 9(1):37-41. PubMed ID: 22634906
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
19. Extended release nicotinic acid - a novel oral agent for phosphate control.
Sampathkumar K; Selvam M; Sooraj YS; Gowthaman S; Ajeshkumar RN
Int Urol Nephrol; 2006; 38(1):171-4. PubMed ID: 16502077
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
